Summary of the UPICT Protocol for <sup>18</sup>F-FDG PET/CT Imaging in Oncology Clinical Trials

Graham, Michael M.; Wahl, Richard L.; Hoffman, John M.; Yap, Jeffrey T.; Sunderland, John; Boellaard, Ronald; Perlman, Eric S.; Kinahan, Paul E.; Christian, Paul E.; Hoekstra, Otto S.; Dorfman, Gary S.

doi:10.2967/jnumed.115.158402

Cited by 97 publications

(110 citation statements)

References 5 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…18 F-FDG PET/CT scanning was performed according to the Uniform Protocols for Imaging in Clinical Trials Protocol for 18 F-FDG PET/CT Imaging in Oncology Clinical Trials (22). Low-dose CT images were acquired for tissue attenuation correction and anatomic correlation.…”

Section: Imagingmentioning

confidence: 99%

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Imagingmentioning

confidence: 99%

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…A protocol to guide the upfront performance of 18 F-FDG PET/ CT studies within the context of single-and multiple-center clinical trials has been published (48). It provides standards for all phases of imaging in oncological trials.…”

Section: Multicenter Studies and Reproducibility Of Resultsmentioning

confidence: 99%

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

Venema

Glaudemans

et al. 2016

J Nucl Med

Self Cite

View full text Add to dashboard Cite

Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 different PET tracers have been or are presently being tested. With a good rationale, after development of the tracer and proven feasibility, it is of interest to evaluate whether there is a potential meaningful role for the tracer in the clinical setting-such as in staging, in the (early) prediction of a treatment response, or in supporting drug choices. So far, only 18 F-FDG PET has been incorporated into breast cancer guidelines. For proof of the clinical relevance of tracers, especially for analysis in a multicenter setting, standardization of the technology and access to the novel PET tracer are required. However, resources for PET implementation research are limited. Therefore, next to randomized studies, novel approaches are required for proving the clinical value of PET tracers with the smallest possible number of patients. The aim of this review is to describe the process of the development of PET tracers and the level of evidence needed for the use of these tracers in breast cancer. Several breast cancer trials have been performed with the PET tracers 18 F-FDG, 3′-deoxy-3′-18 F-fluorothymidine ( 18 F-FLT), and 18 F-fluoroestradiol ( 18 F-FES). We studied them to learn lessons for the implementation of novel tracers. After defining the gap between a good rationale for a tracer and implementation in the clinical setting, we propose solutions to fill the gap to try to bring more PET tracers to daily clinical practice. Mol ecular imaging with PET is a rapidly emerging approach in oncology. This approach offers the potential to noninvasively determine tumor staging, make tumor response measurements, and characterize relevant drug targets in the tumor. Moreover, the wholebody 3-dimensional image provides information about all tumor lesions within a patient. This information is increasingly of potential interest because of progressive awareness of the existence of tumor heterogeneity for several clinical relevant characteristics (1,2). Interestingly, the development of tracers for most hallmarks of cancer allows the imaging of key characteristics of tumors in the research setting (3). More than 30 different PET tracers have been analyzed for their contributions to staging or early response measurements in breast cancer (Table 1). In addition, in the past 5 y, information on 15 different breast cancer tracers has been published. Many more are expected. However, at present, only the visualization of glucose uptake with 18 F-FDG PET is part of standard care and has been incorporated into breast cancer guidelines (4,5). New initiatives are attempting to bridge the gap between new chemical entities and clinical-grade radiopharmaceuticals, which then must be brought to the clinical setting. This process requires proof-of-concept feasibility studies; when sufficient evidence has accumulated, the tracer should be implemented in the clinical setting.The aims of this review are to summarize the steps from preclinical to ...

show abstract

“…QIBA has created validated datasets including ones that can be used for evaluating lung nodules9 and phantom datasets that are used to validate analytical tools such as dynamic contrast enhanced MRI 10. The Uniform Protocols for Imaging in Clinical Trials (UPICT) initiative has created a protocol for trials involving imaging with FDG‐PET/CT 11. Several groups within the AAPM are actively advancing the use of quantitative imaging information, and guidance will continue to evolve in this area.…”

Section: Imagingmentioning

confidence: 99%

Executive summary of AAPM Report Task Group 113: Guidance for the physics aspects of clinical trials

Moran

Molineu

Kruse

et al. 2018

J Applied Clin Med Phys

View full text Add to dashboard Cite

The charge of AAPM Task Group 113 is to provide guidance for the physics aspects of clinical trials to minimize variability in planning and dose delivery for external beam trials involving photons and electrons. Several studies have demonstrated the importance of protocol compliance on patient outcome. Minimizing variability for treatments at different centers improves the quality and efficiency of clinical trials. Attention is focused on areas where variability can be minimized through standardization of protocols and processes through all aspects of clinical trials. Recommendations are presented for clinical trial designers, physicists supporting clinical trials at their individual clinics, quality assurance centers, and manufacturers.

show abstract

Summary of the UPICT Protocol for ¹⁸F-FDG PET/CT Imaging in Oncology Clinical Trials

Cited by 97 publications

References 5 publications

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

Executive summary of AAPM Report Task Group 113: Guidance for the physics aspects of clinical trials

Contact Info

Product

Resources

About

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials

Cited by 97 publications

References 5 publications

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

Executive summary of AAPM Report Task Group 113: Guidance for the physics aspects of clinical trials

Contact Info

Product

Resources

About

Summary of the UPICT Protocol for ¹⁸F-FDG PET/CT Imaging in Oncology Clinical Trials

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma